Local administration of type III phosphodiesterase inhibitors fo

Details Local administration of type III phosphodiesterase inhibitors fo Local administration of type III phosphodiesterase inhibitors fo

1999-11-10

2000-12-05

Reamer, James H.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

514312, A61K 3150

Patent

active

061567531

ABSTRACT:
A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type III phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, wherein administration is transurethral, topical or transdermal. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.

REFERENCES:
patent: 3819631 (1974-06-01), Broughton et al.
patent: 3933822 (1976-01-01), Broughton et al.
patent: 4039544 (1977-08-01), Broughton et al.
patent: 4666908 (1987-05-01), Hamilton
patent: 4801587 (1989-01-01), Voss et al.
patent: 5145852 (1992-09-01), Virag
patent: 5242391 (1993-09-01), Place et al.
patent: 5250534 (1993-10-01), Bell et al.
patent: 5272147 (1993-12-01), Bell et al.
patent: 5346901 (1994-09-01), Bell et al.
patent: 5426107 (1995-06-01), Bell et al.
patent: 5506347 (1996-04-01), Erion et al.
Bush et al. (1992), "Nitric Oxide is a Potent Relaxant of Human and Rabbit Corpus Cavernosum," The Journal of Urology 147:1650-1655.
Doherty (1997), "Oral, Transdermal, and Transurethral Therapies for Erectile Dysfunction," Male Infertility and Dysfunction, Springer-Verlag New York, Inc., pp. 452-467.
Rajfer et al. (1992), "Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission," The New England Journal of Medicine 326(2):90-94.
Taher et al. (1992), "Cyclic Nucleotide Phosphodiesterase Activity in Human Cavernous Smooth Muscle and the Effect of Various Selective Inhibitors," International Journal of Importence Research, Basic and Clinical Studies 4(2):11.
Trigo-Rocho et al. (1993), "The Role of Cyclic Adenosine Monophosphate, Cyclic Guanosine Monophosphate, Endothelium and Nonadreenergic, Noncholinergic Neurotransmission in Canine Penile Erection," The Journal of Urology 149:872-877.
Bivalacqua et al. (1999), "Potentiation of Erectile Response and cAMP Accumulation by Combination of Prostaglandin E.sub.1 and Rolipram, a Selective Inhibitor of the Type 4 Phosphodiesterase (PDE 4)," The Journal of Urology 162:1-8.
Boolell et al. (1996), "Sildenafil: An Orally Active Type 5 Cyclic GMP-Specific Phosphodiesterase Inhibitor for the Treatment of Penil Erectile Dysfunction," International Journal of Impotence Research 8:47-52.
Degerman et al. (1996), "cGMP-Inhibited Phosphodiesterase (PDE3 Gene Family)," Biochemical Society Transactions 24(4):1010-1014.
Degerman et al. (1998), "Phosphorylation and Activation of Hormone-Sensitive Adipocyte Phosphodiesterase Type 3B," Methods: A companion to Methods in Enzymology 14:43-53.
Komas et al. (1996), "cGMP-Inhibited Phosphodiesterase (PDE3)," Phosphodiesterase Inhibitors, Academic Press, Harcourt Brace and Company, Publishers, pp. 89-109.
Martinez-Pineiro et al. (1993), "Cyclic Guanosine Monophosphate Mediates Penile Erection in the Rat," European Urology 24:492-499.
Polson et al. (1996), "Cyclic Nucleotide Phosphodiesterases and Vascular Smooth Muscle," Annu. Rev. Pharmacol. Taxicol. 36:403-427.
Shimizu et al. (1999), "OPC-13013, A Cyclic Nucleotide Phosphodiesterase Type III Inhibitor, Inhibits Cell Proliferation and Transdifferentiation of Cultured Rat Hepatic Stellate Cells," Life Sciences 64(23):2081-2088.
Sparwasser et al. (1994), "Smooth Muscle Tone Regulation in Rabbit Cavernosal and Spongiosal Tissue by Cyclic AMP- and Cyclic GMP-Dependent Mechanisms," The Journal of Urology 152:2159-2163.
Stief et al. (1995), "Cyclic Nucleotide Phosphodiesterase (PDE) Isoenzymes in Human Cavernous Smooth Muscle: Characterization and Functional Effects of PDE-Inhibitors In Vitro and In Vivo," International Journal of Impotence Research, Basic and Clinical Studies 7(1):6-7.
Suzumura et al. (1999), "Ibudilast Suppresses TNF.alpha. Production By Glial Cells Functioning Mainly as Type III Phosphodiesterase Inhibitor in the CNS," Brain Research 837:203-212.
Taher et al. (1997), "Cyclic Nucleotide Phosphodiesterase in Human Cavernous Smooth Muscle," World Journal of Urology 15:32-35.

Affiliated with

Also associated with

Rating

Local administration of type III phosphodiesterase inhibitors fo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Local administration of type III phosphodiesterase inhibitors fo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Local administration of type III phosphodiesterase inhibitors fo will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-961972